WallStreetZenWallStreetZen

NYSE: BMY
Bristol Myers Squibb Co Stock Forecast, Predictions & Price Target

Open Broker Account
OverviewForecast
EarningsDividendOwnership

Analyst price target for BMY

Based on 10 analysts offering 12 month price targets for Bristol Myers Squibb Co.
Min Forecast
$61.00-14.19%
Avg Forecast
$75.90+6.77%
Max Forecast
$94.00+32.23%

Should I buy or sell BMY stock?

Based on 12 analysts offering ratings for Bristol Myers Squibb Co.
Buy
Strong Buy
3 analysts 25%
Buy
1 analysts 8.33%
Hold
7 analysts 58.33%
Sell
0 analysts 0%
Strong Sell
1 analysts 8.33%

Be the first to know when Wall Street analysts revise their BMY stock forecasts and price targets.

BMY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Berenberg
Top 40%
61
HoldDowngrades$76.00+6.91%2022-09-14
BMO Capital
Bottom 10%
10
BuyMaintains$94.00+32.23%2022-09-12
Atlantic Equities
Bottom 30%
30
Strong BuyMaintains$87.00+22.38%2022-09-12
Morgan Stanley
Top 16%
85
Strong SellMaintains$61.00-14.19%2022-07-28
UBS
Bottom 1%
1
HoldMaintains$75.00+5.50%2022-07-28
Raymond James
Bottom 4%
4
HoldDowngradesN/AN/A2022-06-06
Citigroup
Top 18%
83
Strong BuyMaintains$90.00+26.60%2022-05-26
Wells Fargo
Top 14%
87
HoldMaintains$70.00-1.53%2022-05-17
Anonymous
Morgan Stanley
Strong SellMaintains$63.00-11.38%2022-05-02
Barclays
Bottom 17%
17
HoldMaintains$68.00-4.35%2022-05-02

1 of 2

Forecast return on equity

Is BMY forecast to generate an efficient return?
Company
55.8%
Industry
91.67%
Market
121.74%
BMY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BMY forecast to generate an efficient return on assets?
Company
18.13%
Industry
17.84%
BMY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BMY earnings per share forecast

What is BMY's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$7.51+147.04%
Avg 2 year Forecast
$8.10+166.45%
Avg 3 year Forecast
$8.17+168.75%
BMY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

BMY revenue forecast

What is BMY's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$45.9B-2.54%
Avg 2 year Forecast
$47.7B+1.28%
Avg 3 year Forecast
$48.8B+3.41%
BMY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BMY earnings growth forecast

How is BMY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
39.7%
Industry
13.64%
Market
16.88%
BMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BMY revenue growth forecast

How is BMY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
1.13%
Industry
0.94%
Market
8.59%
BMY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BMY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BMY vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
BMY$71.09$75.90+6.77%Buy
NVS$76.01N/AN/AHold
AZN$54.84$75.00+36.76%Buy
AMGN$225.40$239.50+6.26%Hold
SNY$38.02N/AN/AHold
View Top General Drug Manufacturer Stocks

Bristol Myers Squibb Co Stock Forecast FAQ

Is Bristol Myers Squibb Co Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NYSE: BMY) stock is to Buy BMY stock.

Out of 12 analysts, 3 (25%) are recommending BMY as a Strong Buy, 1 (8.33%) are recommending BMY as a Buy, 7 (58.33%) are recommending BMY as a Hold, 0 (0%) are recommending BMY as a Sell, and 1 (8.33%) are recommending BMY as a Strong Sell.

If you're new to stock investing, here's how to buy Bristol Myers Squibb Co stock.

What is BMY's earnings growth forecast for 2022-2024?

(NYSE: BMY) Bristol Myers Squibb Co's forecast annual earnings growth rate of 39.7% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 13.64%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Bristol Myers Squibb Co's earnings in 2022 is $6,617,000,000.On average, 8 Wall Street analysts forecast BMY's earnings for 2022 to be $16,035,766,237, with the lowest BMY earnings forecast at $15,864,945,824, and the highest BMY earnings forecast at $16,249,291,752. On average, 9 Wall Street analysts forecast BMY's earnings for 2023 to be $17,295,566,780, with the lowest BMY earnings forecast at $16,676,342,784, and the highest BMY earnings forecast at $17,850,733,121.

In 2024, BMY is forecast to generate $17,445,034,641 in earnings, with the lowest earnings forecast at $15,651,420,308 and the highest earnings forecast at $18,790,245,390.

What is BMY's revenue growth forecast for 2022-2024?

(NYSE: BMY) Bristol Myers Squibb Co's forecast annual revenue growth rate of 1.13% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 0.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.59%.

Bristol Myers Squibb Co's revenue in 2022 is $47,144,000,000.On average, 6 Wall Street analysts forecast BMY's revenue for 2022 to be $98,105,096,819,739, with the lowest BMY revenue forecast at $97,340,730,989,809, and the highest BMY revenue forecast at $98,341,311,556,848. On average, 6 Wall Street analysts forecast BMY's revenue for 2023 to be $101,951,496,350,492, with the lowest BMY revenue forecast at $101,120,538,317,949, and the highest BMY revenue forecast at $103,078,097,541,700.

In 2024, BMY is forecast to generate $104,101,269,108,311 in revenue, with the lowest revenue forecast at $100,713,667,582,847 and the highest revenue forecast at $106,147,590,888,980.

What is BMY's forecast return on assets (ROA) for 2022-2025?

(NYSE: BMY) forecast ROA is 18.13%, which is higher than the forecast US Drug Manufacturers - General industry average of 17.84%.

What is BMY's Price Target?

According to 10 Wall Street analysts that have issued a 1 year BMY price target, the average BMY price target is $75.90, with the highest BMY stock price forecast at $94.00 and the lowest BMY stock price forecast at $61.00.

On average, Wall Street analysts predict that Bristol Myers Squibb Co's share price could reach $75.90 by Sep 14, 2023. The average Bristol Myers Squibb Co stock price prediction forecasts a potential upside of 6.77% from the current BMY share price of $71.09.

What is BMY's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: BMY) Bristol Myers Squibb Co's current Earnings Per Share (EPS) is $3.04. On average, analysts forecast that BMY's EPS will be $7.51 for 2022, with the lowest EPS forecast at $7.43, and the highest EPS forecast at $7.61. On average, analysts forecast that BMY's EPS will be $8.10 for 2023, with the lowest EPS forecast at $7.81, and the highest EPS forecast at $8.36. In 2024, BMY's EPS is forecast to hit $8.17 (min: $7.33, max: $8.80).

What is BMY's forecast return on equity (ROE) for 2022-2025?

(NYSE: BMY) forecast ROE is 55.8%, which is considered strong.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market Industries
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.